Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine and Busulfan +/- Low Dose TBI in Allogeneic Stem Cell Transplant for Myeloid Malignancies
NCT01366612Phase 3Terminated
- Sponsor
- Hackensack Meridian Health
- Start
- Jun 2010
- Primary completion
- Aug 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fludarabine and busulfan in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myeloproliferative disorder (MPD) and 1 more (2 arms), sponsored by Hackensack Meridian Health. Primary endpoint: Relapse Rate at 1 year. Started Jun 2010; status: terminated.
02
Drugs
fludarabinebusulfan
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)myeloproliferative disorder (MPD)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01366612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01366612.